Stammdaten
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase II clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Unternehmen & Branche
| Name | Acurx Pharmaceuticals, Inc. |
|---|---|
| Ticker | ACXP |
| CIK | 0001736243 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 3,2 Mio. USD |
| Beta | -1,92 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -7,966,538 | -5.32 | 7,689,535 | 5,268,592 | |
| 2025-09-30 | 10-Q | -1,992,790 | -1.23 | 6,105,211 | 3,637,036 | |
| 2025-06-30 | 10-Q | -2,246,279 | -1.89 | 3,566,331 | ||
| 2025-03-31 | 10-Q | -2,149,193 | -0.11 | 2,311,399 | ||
| 2024-12-31 | 10-K | -14,103,103 | -17.45 | 3,857,963 | 615,121 | |
| 2024-09-30 | 10-Q | -2,821,597 | -3.45 | 2,663,994 | ||
| 2024-06-30 | 10-Q | -4,121,826 | -5.21 | 6,580,392 | 3,427,475 | |
| 2024-03-31 | 10-Q | -4,377,889 | -0.28 | 9,108,834 | 5,998,592 | |
| 2023-12-31 | 10-K | -14,577,768 | -1.15 | 7,709,123 | 4,666,685 | |
| 2023-09-30 | 10-Q | -3,114,981 | -0.24 | 3,934,673 | ||
| 2023-06-30 | 10-Q | -3,445,240 | -0.28 | 6,216,369 | ||
| 2023-03-31 | 10-Q | -2,902,957 | -0.25 | 5,311,439 | ||
| 2022-12-31 | 10-K | -12,092,776 | -1.12 | 9,376,706 | 7,315,021 | |
| 2022-09-30 | 10-Q | -3,541,594 | -0.32 | 9,763,068 | ||
| 2022-06-30 | 10-Q | -2,620,533 | -0.26 | 9,259,300 | 8,785,421 | |
| 2022-03-31 | 10-Q | -2,670,138 | -0.26 | 11,322,300 | 10,689,272 | |
| 2021-12-31 | 10-K | -12,747,697 | -1.49 | 13,254,150 | 12,410,241 | |
| 2021-09-30 | 10-Q | -4,642,222 | -0.46 | 14,989,628 | 14,277,191 | |
| 2021-06-30 | 10-Q | -4,004,059 | -0.57 | 17,440,145 | 15,521,506 | |
| 2021-03-31 | 10-Q | -1,474,330 | -0.21 | 2,471,159 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.